Abstract:<h3 class="Heading">Aims/hypothesis</h3><p class="Para">Diabetic peripheral neuropathy (DPN) is one of the major complications of diabetes, which contributes greatly to morbidity and mortality. There is currently no effective treatment for this disease. Exosomes are cell-derived nanovesicles and play an important role in intercellular communications. The present study investigated whether mesenchymal stromal cell (MSC)-derived exosomes improve neurological outcomes of DPN.</p><h3 class="Heading">Methods</h3><p class="Para">Exosomes were isolated from the medium of cultured mouse MSCs by ultracentrifugation. Diabetic mice (BKS.Cg<em class="EmphasisTypeItalic">-m+/+Lepr</em><sup><em class="EmphasisTypeItalic">db</em></sup><em class="EmphasisTypeItalic">/J</em>, <em class="EmphasisTypeItalic">db/db</em>) at the age of 20 weeks were used as DPN models. Heterozygous mice (<em class="EmphasisTypeItalic">db</em>/m) of the same age were used as the control. MSC-exosomes were administered weekly via the tail vein for 8 weeks. Neurological function was evaluated by testing motor and sensory nerve conduction velocities, and thermal and mechanical sensitivity. Morphometric analysis was performed by myelin sheath staining and immunohistochemistry. Macrophage markers and circulating cytokines were measured by western blot and ELISA. MicroRNA (miRNA) array and bioinformatics analyses were performed to examine the exosomal miRNA profile and miRNA putative target genes involved in DPN.</p><h3 class="Heading">Results</h3><p class="Para">Treatment of DPN with MSC-exosomes markedly decreased the threshold for thermal and mechanical stimuli and increased nerve conduction velocity in diabetic mice. Histopathological analysis showed that MSC-exosomes markedly augmented the density of FITC-dextran perfused blood vessels and increased the number of intraepidermal nerve fibres (IENFs), myelin thickness and axonal diameters of sciatic nerves. Western blot analysis revealed that MSC-exosome treatment decreased and increased M1 and M2 macrophage phenotype markers, respectively. Moreover, MSC-exosomes substantially suppressed proinflammatory cytokines. Bioinformatics analysis revealed that MSC-exosomes contained abundant miRNAs that target the Toll-like receptor (TLR)4/NF-κB signalling pathway.</p><h3 class="Heading">Conclusions/interpretation</h3><p class="Para">MSC-derived exosomes alleviate neurovascular dysfunction and improve functional recovery in mice with DPN by suppression of proinflammatory genes.</p>

Nanoparticle-microRNA-146a-5p Polyplexes Ameliorate Diabetic Peripheral Neuropathy by Modulating Inflammation and Apoptosis.

Mesoporous Silica Particles As a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

MicroRNA‐7a‐5p ameliorates diabetic peripheral neuropathy by regulating VDAC1/JNK/c‐JUN pathway

MicroRNA-146a Mimics Reduce the Peripheral Neuropathy in Type 2 Diabetic Mice

Blocking CXC Motif Chemokine Ligand 2 Ameliorates Diabetic Peripheral Neuropathy Via Inhibiting Apoptosis and NLRP3 Inflammasome Activation.

Long Non-coding RNA XIST Attenuates Diabetic Peripheral Neuropathy by Inducing Autophagy Through MicroRNA-30d-5p/sirtuin1 Axis

Treatment of diabetic peripheral neuropathy with engineered mesenchymal stromal cell-derived exosomes enriched with microRNA-146a provide amplified therapeutic efficacy

Mir-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-Lox-meidiated Oxidative/Nitrative Stress

SIRT1-Enriched Exosomes Derived from Bone Marrow Mesenchymal Stromal Cells Alleviate Peripheral Neuropathy via Conserving Mitochondrial Function

Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes

Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy

Non-coding RNAs in diabetic peripheral neuropathy: their role and mechanisms underlying their effects

siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model

Mir-590-3p Alleviates Diabetic Peripheral Neuropathic Pain by Targeting RAP1A and Suppressing Infiltration by the T Cells

The circ_0002538/miR-138-5p/PLLP axis regulates Schwann cell migration and myelination in diabetic peripheral neuropathy

VEGF-loaded ROS-responsive Nanodots Improve the Structure and Function of Sciatic Nerve Lesions in Type II Diabetic Peripheral Neuropathy.

Treatment with Tang-luo-ning altered the microRNA expression profile in rats with diabetic peripheral neuropathy.

DW14006 as a Direct AMPK Activator Ameliorates Diabetic Peripheral Neuropathy in Mice

Effect of Metformin Nanoemulsion Through AMP-activated Protein Kinase (Ampk)-Mediated Autophagy on Diabetic Neuropathy

Curcumin Ameliorates the Experimental Diabetic Peripheral Neuropathy Through Promotion of NGF Expression in Rats.

Beneficial Effect Of Tnf-Alpha Inhibition On Diabetic Peripheral Neuropathy